News | October 17, 2025
Healthium partners with US-based Tisgenx to bring cardiac innovations to India
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Subscribe To Our Newsletter & Stay Updated
